Charles University in Prague

About: Charles University in Prague is a education organization based out in Prague, Czechia. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 32392 authors who have published 74435 publications receiving 1804208 citations.

Very high-energy gamma rays from the direction of Sagittarius A*

Abstract: We report the detection of a point-like source of very high energy (VHE) gamma-rays coincident within 1' of Sgr A*, obtained with the H.E.S.S. array of Cherenkov telescopes. The gamma-rays exhibit a power-law energy spectrum with a spectral index of -2.2 +/- 0.09 +/- 0.15 and a flux above the 165 GeV threshold of (1.82 +/- 0.22) \times 10^{-7} m^{-2} s^{-1}. The measured flux and spectrum differ substantially from recent results reported in particular by the CANGAROO collaboration.

Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System.

Abstract: Interventional radiology provides a wide variety of vascular, nonvascular, musculoskeletal, and oncologic minimally invasive techniques aimed at therapy or palliation of a broad spectrum of pathologic conditions. Outcome data for these techniques are globally evaluated by hospitals, insurance companies, and government agencies targeting in a high-quality health care policy, including reimbursement strategies. To analyze effectively the outcome of a technique, accurate reporting of complications is necessary. Throughout the literature, numerous classification systems for complications grading and classification have been reported. Until now, there has been no method for uniform reporting of complications both in terms of definition and grading. The purpose of this CIRSE guideline is to provide a classification system of complications based on combining outcome and severity of sequelae. The ultimate challenge will be the adoption of this system by practitioners in different countries and health economies within the European Union and beyond.

Efficient partition trees

Abstract: We prove a theorem on partitioning point sets inEd (d fixed) and give an efficient construction of partition trees based on it. This yields a simplex range searching structure with linear space,O(n logn) deterministic preprocessing time, andO(n1?1/d(logn)O(1)) query time. WithO(nlogn) preprocessing time, where ? is an arbitrary positive constant, a more complicated data structure yields query timeO(n1?1/d(log logn)O(1)). This attains the lower bounds due to Chazelle [C1] up to polylogarithmic factors, improving and simplifying previous results of Chazelleet al. [CSW]. The partition result implies that, forrd≤n1??, a (1/r)-approximation of sizeO(rd) with respect to simplices for ann-point set inEd can be computed inO(n logr) deterministic time. A (1/r)-cutting of sizeO(rd) for a collection ofn hyperplanes inEd can be computed inO(n logr) deterministic time, provided thatr≤n1/(2d?1).

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Abstract: Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF V600 -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. Methods COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAF V600E or BRAF V600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had progressed on or after first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) by use of interactive response technology to receive oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). Randomisation was stratified by the American Joint Committee on Cancer stage, ECOG performance status, and BRAF mutation status. The primary outcome of the trial, progression-free survival with encorafenib plus binimetinib versus vemurafenib, was reported previously. Here we present the prespecified interim overall survival analysis. Efficacy analyses were by intent to treat. Safety was analysed in patients who received at least one dose of study drug. Part 2 of the study was initiated at the request of the US Food and Drug Administration to better understand the contribution of binimetinib to the combination therapy by comparing encorafenib 300 mg once daily plus binimetinib 45 mg twice daily with encorafenib 300 mg once daily alone. Results of part 2 will be published separately. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38. Findings Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to receive encorafenib plus binimetinib (n=192), encorafenib (n=194), or vemurafenib (n=191). Median follow-up for overall survival was 36·8 months (95% CI 35·9–37·5). Median overall survival was 33·6 months (95% CI 24·4–39·2) with encorafenib plus binimetinib and 16·9 months (14·0–24·5) with vemurafenib (hazard ratio 0·61 [95% CI 0·47–0·79]; two-sided p Interpretation The combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAF V600 -mutant melanoma. Funding Array BioPharma, Novartis.